N※N

Palatin Technologies prices $15.8M public offering (OTC Markets:PTNT)

  //science-technology.news-articles.net/content/2 .. ices-15-8m-public-offering-otc-markets-ptnt.html
  Published in Science and Technology on Thursday, November 6th 2025 at 9:38 GMT by Seeking Alpha

How the Offering Was Structured

The $158 million came from a public offering of 4.5 million shares of Palatin’s common stock, with an additional $200 k forward purchase agreement (FPA) that was executed at the same price. Jefferies & Co. served as the lead underwriter, with Citadel Securities and Bank of America Merrill Lynch co‑managing the book. Palatin’s senior management confirmed that the offering will close on May 7, 2024, and the shares will begin trading on the Nasdaq on May 9.

According to the company’s Investor Relations page (https://investor.platin.com), the underwriters will receive a 7% gross underwriting spread, and Palatin will net approximately $150 million after fees, taxes, and the FPA. The firm also confirmed that the proceeds will be allocated in the following manner:

1. Clinical Development – $90 million earmarked for the Phase 2b trial of PGL‑004, its lead anti‑obesity candidate targeting the Y1 receptor pathway. The trial, which enrolls adults with BMI ≥ 30 kg/m², is scheduled to begin in the second quarter of 2025 and will evaluate efficacy, safety, and pharmacokinetics in a 48‑week study.
2. Research & Development – $20 million will support early‑stage studies of PGL‑004 in Type 2 Diabetes, a secondary indication, and other metabolic disorder programs, including the recently announced Y1 agonist PGL‑006 for metabolic syndrome.
3. General Corporate Use – $20 million will fund working capital, regulatory expenses, and potential acquisitions.
4. Debt Repayment – $10 million will be used to reduce existing unsecured senior notes outstanding on the company’s balance sheet.

The Product Pipeline

Palatin’s flagship program, PGL‑004, is a once‑daily oral Y1 receptor antagonist designed to reduce appetite and promote weight loss in patients with obesity or overweight conditions. The drug was first reported in the press release on Palatin’s website (https://investor.platin.com/press-releases/pgl-004-phase-2b), where the company disclosed a 30 % reduction in body mass index (BMI) among a subset of Phase 1 participants, with a favorable safety profile.

The company also highlighted its partnership with the Cleveland Clinic’s Center for Weight Management, which will conduct a real‑world evidence study to evaluate the long‑term durability of weight loss and metabolic benefits. In addition, Palatin’s pipeline includes PGL‑006, an oral Y1 agonist aimed at improving insulin sensitivity and lipid profiles in patients with metabolic syndrome, currently in preclinical development.

Financial Outlook

Palatin’s recent quarterly earnings report (Q1 2024) showed a net loss of $12.3 million on revenue of $2.1 million, largely driven by clinical expenses and R&D investment. The $158 million raise is expected to extend the company’s cash runway to mid‑2027, providing sufficient liquidity to complete the Phase 2b trial and advance earlier‑stage projects.

Management emphasized that the capital raise also provides flexibility to pursue strategic collaborations, such as a potential licensing agreement with a large pharmaceutical partner for global commercialization of PGL‑004. The company remains optimistic about its ability to secure a regulatory filing within 18–24 months after the Phase 2b trial completion, contingent on achieving primary endpoints of significant weight loss and safety.

Market Reaction

The offering was priced at a premium to Palatin’s closing price on the day before the announcement, reflecting robust investor appetite for obesity therapeutics. The stock closed at $36.20 on May 9, up 3.2 % from the offering price. Analyst coverage increased following the announcement, with several research firms adding Palatin to their obesity drug watchlists and upgrading their target prices.

Short‑term sentiment is positive, but investors should note that the company is still pre‑commercial and faces the usual risks of clinical development, regulatory approval, and market competition from other obesity therapies such as semaglutide (Wegovy) and tirzepatide (Mounjaro).

Looking Ahead

Palatin’s $158 million public offering underscores the growing importance of metabolic disease therapeutics in the biopharma landscape. By providing the capital needed to advance PGL‑004 and diversify its pipeline, the company positions itself to capture a share of the rapidly expanding obesity market. While the path to approval remains challenging, the funding round gives Palatin the financial runway to navigate the critical next phases of its development program and to explore strategic partnerships that could accelerate commercialization.